Amytrx Therapeutics Raises $18M For New Therapeutic Interventions Of Atopic Dermatitis
05/25/22, 10:00 AM
Location
nashvilleMoney raised
$18 million
Amytrx Therapeutics, a mission-driven biopharmaceutical company dedicated to transformative and cutting-edge immune-modulating therapeutics that safely alter the course of chronic inflammatory disorders, announces today it has concluded its $18M in Series A financing with participation from both existing and new investors. This funding is dedicated to continuing clinical research on the use of their next-generation anti-inflammatory therapeutic peptide platform, AMTX-100, across several skin inflammatory disorders in adults and adolescents.
Company Info
Location
nashville, arkansas, united states
Additional Info
Amytrx is a clinical-stage biopharmaceutical company pioneering the first anti-inflammatory human peptide platform (AMTX-100) yielding the potential for vastly optimized, cutting-edge therapies that safely alter the course of chronic inflammation and metabolic dysfunction to prevent and treat some of the world's most debilitating diseases. For further information please visit www.amytrx.com.
1 https://pubmed.ncbi.nlm.nih.gov/30389491/2 https://pubmed.ncbi.nlm.nih.gov/25925336/3 https://www.ncbi.nlm.nih.gov/books/NBK448071/4 https://www.nature.com/articles/s41573-021-00266-65 https://pubmed.ncbi.nlm.nih.gov/31301006/
SOURCE Amytrx Therapeutics